Deficitul de fier şi anemia în insuficienţa cardiacă

Ana Maria Vlădăreanu; Leonida  Gherasim

doi:10.5281/zenodo.10093811

Authors

Ana Maria Vlădăreanu 1.Spitalul Universitar de Urgență București 2.Universitatea de Medicină și Farmacie „Carol Davila” București
Leonida Gherasim Academia Română

DOI:

https://doi.org/10.5281/zenodo.10093811

Keywords:

anemie, deficit de fier, feriprivie, insuficiență cardiaca, corecție deficit fier, ferric carboxymaltoză, ferric derisomaltoză

Abstract

Sindromul complex al insuficienţei cardiace are faţete multiple, etiologice, patogenice, clinice şi evolutive. În evoluţia pe termen lung (clinică) se asociază cu multiple tipuri de comorbidităţi, care au impact pe morbiditate, calitatea vieţii şi mortalitate.

Deficitul de fier şi anemia în insuficienţa cardiacă (IC) a devenit un subiect major de cercetare complexă în ultimii 10-15 ani. Studiile epidemiologice au semnalat (demonstrat) că deficitul de fier se întâlneşte la aprox. 50% din pacienţii cu IC şi FE redusă şi că este independent asociat cu scăderea capacităţii funcţionale, calitatea vieţii şi creşterea mortalităţii (1). La pacienţii cu IC acută (sau decompensată acut) deficitul de fier s-ar întâlni până la 80%. Studiile au mai semnalat că deficitul de fier se poate însoţi sau nu de anemie, iar administrarea unor preparate de fier i.v. corectează anemia, restabileşte valorile sideremiei şi ameliorează simptomele şi capacitatea de efort la pacienţii cu IC şi FE redusă (2).

References

Beavers C.J, Ambrosy A.P, Butler J, et al – “Iron deficiency in heart failure: a scientific statement from the Heart failure Society of America” – J Card Fail 2023, 29, 1059-1077

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009 Dec 17;361(25):2436–48.

Zhang AS, Enns C. Molecular mechanisms of normal iron homeostasis. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2009 Dec 11;1:207–14.

Finberg KE. Regulation of systemic iron homeostasis. Curr Opin Hematol. 2013 May 1;20(3):208–14.

Von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron Deficiency in Heart Failure: An Overview. JACC Heart Fail. 2019 Jan;7(1):36–46.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599–726.

Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, et al. Criteria for Iron Deficiency in Patients With Heart Failure. J Am Coll Cardiol. 2022 Feb 1;79(4):341–51.

Graham F.J, Masini G, Pellicari P, et al – “Natural history and prognostic significance of iron deficiency and anemia in ambulatory patients with chronic heart failure” – Eur J Heart Fail 2022, 24: 807-17

Van der Wal H.H, Beverborg N.G, Dickstein K – “Iron deficiency in worsening heart failure is associated with reduce estimated protein intake, fluid retention, inflammation and antiplatelet use” – Eur Heart J 2019, 40: 3616-21

Dick SA, Epelman S. Chronic Heart Failure and Inflammation: What Do We Really Know? Circ Res. 2016 Jun 24;119(1):159–76.

Camaschella C, Nai A, Silvestri L – “Iron metabolism and iron disorders revisited in the hepcidin era” – Haematologica 2020, 105: 260

Martens P – “The effect on iron deficiency on cardiac function and structure in heart failure with reduced ejection fraction” – Card Fail Rev 2022, Mar 16

Mullens W – “Treating Iron Deficiency in heart failure” – N Engl J Med 2023, 389: 1041-1042

Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA. 2017 May 16;317(19):1958–66.

Heindenreich P.A, Bozkurt B, Aguilar D, et al – “2022 American College of Cardiology/ American Heart Association/ American, Heart Failure Society of America – Guideline for the management of Heart failure. Executive Summary” – J Card Fail 2022, 28: 810-30

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015 Mar 14;36(11):657–68.

Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018 Jan;20(1):125–33.

Ponikowski P, Kirwan B.A, Anker S.D, et al – “Ferric carboxymaltose for iron deficiency at discharge after acute heart failure” – Lancet 2020, 396: 1895

Kalra P.R, Cleland J.C.F, Petrie M.C, et al – “Intravenous ferric derisomaltose in heart failure and iron deficiency in the UK (IRONMAN)” – Lancet 2022, 400: 2199

Hamza M, Sattar Y, Manasrah N, Patel NN, Rashdi A, Khanal R, et al. Meta-Analysis of Efficacy and Safety of Intravenous Iron in Patients With Iron Deficiency and Heart Failure With Reduced Ejection Fraction. Am J Cardiol. 2023 Sep 1;202:119–30.

Swedberg K, Young J.B, Anand I.S, et al – “Treatment of anemia with darbepoetin alfa in systolic heart failure” – N Engl J Med 2013, 368: 1210-19